Condition: Colorectal Cancer Metastatic · Sponsor: Chinese PLA General Hospital
Phase II clinical study of irinotecan liposome (II)-based combination regimen as a treatment for irinotecan-resistant colorectal cancer.
This description comes directly from the study's public registry record.
Guanghai Dai, Doctor · +861066947252 · daigh301@vip.sina.com
Always discuss trial participation with your own doctor first.
| Chinese PLA General Hospital, Beijing, | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07044921